资讯 | 贸易局势进展推动,道指标普创收盘新高

wechat omage

美股

北京时间11月8日凌晨,美股周四收高,道指与标普500指数刷新收盘历史纪录。国际贸易局势出现积极进展,促使投资者抛售债券投入股市。

截止收盘,道指收盘上涨182.24点,或0.66%,报27674.80点;标普500指数涨8.40点,或0.27%,报3085.18点;纳指涨23.89点,或0.28%,报8434.52点。

道指与标普500指数均创收盘新高,纳指逼近周二创造的历史最高收盘纪录8434.68点。周四早间,道指最高上涨至27774.67点,标普500指数上涨至3097.77点,纳指上涨至8483.16点,均创盘中历史新高。

受国际贸易关系进展的消息推动,卡特彼勒(147.01, 1.52, 1.04%)(CAT)、波音(357.31, 5.18, 1.47%)(BA)等涨幅均超过1%。美光(48.4, 0.72, 1.51%)科技(MU)、AMD(36.28, 0.35, 0.97%)与Skyworks Solutions等芯片股悉数攀升。

国际贸易关系进展激起乐观情绪,促使投资者抛售美债。美国10年期国债收益率从周三的1.81%攀升至1.95%,录得特朗普当选美国总统以来的最大日涨幅。国债价格下跌则收益率上涨。

近来美股表现似乎与国际贸易关系的进展密切相关。分析师指出,过去24小时内,有关国际贸易关系进展的消息令美股出现波动,周三出现的相对负面的消息造成市场压抑,周四的利好消息则推动美股攀升。

焦点个股:

高通(89.98, 5.35, 6.32%)(QCOM)收盘大涨6.3%。该公司宣布季度业绩超出预期。该公司2019财年营业利润录得77亿美元;净利润44亿美元,上年同期亏损50亿美元。高通2019财年总营收为242.73亿美元,苹果(259.43, 2.96, 1.15%)的“赔款”约占公司总营收的19.36%,依靠这笔巨款,高通摆脱了连续五年的营收下降。高通指出,2019财年第三季度与苹果及其合同制造商达成的和解协议产生了47亿美元的营收,合每股收益3.23美元,但并未计入其部门业绩。

美国珠宝连锁企业蒂芙尼(125, 0.31, 0.25%)(TIF)已要求LV母公司法国奢侈品巨头LVMH集团提高其145亿美元的收购报价,理由是大大低估了公司价值。

流媒体视频公司Roku股价重挫,该公司第三季度销售额为2.609亿美元,每股亏损0.22美元。

百度(121.87, 14.51, 13.52%)宣布第三季度总营收为人民币280.80亿元,略低于去年同期的人民币282.03亿元。

爱奇艺(20, 2.54, 14.55%)第三季度营收达到74亿元人民币(约合10亿美元),同比增长7%。在第三季度末,订阅会员规模达到1.058亿,订阅会员规模同比增长31%。
 

   

港股

北京时间11月7日,美股周三收盘基本持平,纳指结束此前连续三个交易日上涨的行情。投资者继续关注国际贸易关系方面的不确定性因素、美企财报及并购消息等。周四开盘,港股恒指小幅高开0.01%,午后直线拉升至翻红,一度涨0.7%。

截至收盘,恒生指数涨0.57%,报27847.23点。国企指数涨0.69%,报10935.89点;红筹指数涨0.69%,报4429.14点

热点板块:内地医药股上涨。复星医药涨5.31%;康哲药业涨7.51%;石药集团涨4.39%。中资券商股上涨。中信建投涨2.47%;中国银河涨2.33%;海通证券涨1.77%。内银股上涨。甘肃银行涨7.06%;徽商银行涨1.91%;建设银行涨1.71%。区块链概念股上涨。雄岸科技涨16.67%;桐成控股涨20.63%;元征科技涨7.11%。

长江生命科技涨23.33%,昨日暴涨超150%。此前长江生命科技宣布,旗下美国附属公司Polynoma的黑色素瘤抗原疫苗免疫疗法研究的中期数据分析结果,将于本周五(8日)在美国马里兰州举行的癌症免疫疗法学会2019年会中首度展出。长江生命科技主席李泽钜表示,面对庞大的医药需求及市场,科研成果有助患者对抗癌症,得到批准后亦有机会为公司带来盈利贡献。除针对黑色素瘤的seviprotimut-L研发项目外,公司现正研究发展其他癌症疫苗。目前,该黑色素瘤抗原疫苗免疫疗法研究正进行美国食品及药物管理局(FDA)第三阶段临床试验。该公司指出,黑色素瘤疗法的环球市场估值超过10亿美元,预计未来5年将以倍数增长。
 

中国A股

北京时间11月7日,两市小幅低开,随后大盘整体震荡走强,三大股指翻红,创指涨逾1%。临近上午收盘,指数冲高后开始盘整,科创板个股强势爆发,沪指再度转跌。午后,三大股指窄幅震荡,区块链板块午后再度拉升。临近收盘,沪指反弹无力又翻绿,随后跌幅缓慢收窄。总体上,两市个股涨多跌少,成交量持续低迷,赚钱效应一般。

截止收盘,沪指平收,报2978.71点;深成指报9917.49点,涨0.57%。从盘面上看,猪肉、光刻胶、数字中国板块居涨幅榜前列,国防军工、有色钴、钢铁板块居跌幅榜前列。

热点板块:电子竞技板块走强,掌趣科技涨停,中青宝触板,天神娱乐、浙数文化、完美世界纷纷走强。区块链概念持续拉升,先进数通、四方精创涨停,华扬联众、天广中茂、新晨科技纷纷走强。消息面上上海国际贸易单一窗口“区块链+”新闻发布会11月7日上午在国家会展中心(上海)举行。会上,政企双方代表共同签署《上海电子口岸区块链联盟倡议书》,标志着上海电子口岸区块链联盟正式成立。 
 
如果有想了解更多全球股市资讯,请关注微信公众号 “辉立资本新加坡” (SGPSPL)

同时提供在线免费开设股票账户,一个账户轻松交易美股,港股,新加坡股,中国A股,越南股票,韩国股票,德国股票,马来西亚股票,泰国股票,印尼股票,菲律宾股票,日本股票,澳大利亚股票,台湾股票,加拿大股票,英国股票,法国股票,荷兰股票,葡萄牙股票,比利时股票,土耳其股票
 

来源:东方财富网,新浪财经,同花顺,21世纪经济报道,彭博,华尔街见闻,辉立证券

联系我们开设账户

需要帮助吗?请分享您的详细资料,我们会给您答复。

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com